We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

EGFR/HER2

EGFR and HER2 inhibitors act on two closely related receptor tyrosine kinases of the ErbB family. The epidermal growth factor receptor (EGFR, ErbB1) and human epidermal growth factor receptor 2 (HER2, ErbB2) form dimers with each other and with ErbB3 and ErbB4. Receptor activation engages the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways that control cell growth. Activating EGFR mutations in non-small-cell lung cancer have made the receptor a central model in kinase inhibitor research. Gefitinib and erlotinib are reversible EGFR inhibitors, and lapatinib inhibits both EGFR and HER2. Osimertinib binds covalently to EGFR carrying the T790M resistance mutation, and neratinib irreversibly inhibits HER2 and EGFR.

2 Items

  • NSC 228155
    Cat. No.
    A16638
    CAS No.
    113104-25-9

    NSC 228155

    NSC 228155 is an activator of EGFR, binds to the extracellular region of EGFR and enhance tyrosine phosphorylation of EGFR.

    In stock View Details
    5 mg
    $35.00
    10 mg
    $55.00
    All 7 sizes
  • 13(S)-HPODE
    Cat. No.
    A28938
    CAS No.
    33964-75-9

    13(S)-HPODE

    13(S)-HPODE is a linoleic acid metabolite that acts as an EGFR activator. It has demonstrated significant biological activity in promoting cell proliferation and may play a role in various signaling pathways associated with cancer progression and inflammation. This compound is valuable for research into mechanisms of cancer biology and the development of therapeutic strategies targeting the EGFR pathway.

    In stock View Details
    0.05 mg
    $150.00
    0.1 mg
    $345.00
    All 4 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...